Charlene Vitale, MD
Internal Medicine · Rochester, NYNPI 1720099856
Payments from drug & device makers
Across 587 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$1K
- Amgen$1K
- Novo Nordisk$1K
- Pfizer$745
- Bayer$549
- plus $2K from 32 others
What the payments were for
- Food & beverage$8,79198%
- Education$1442%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 161 | $2,026 |
| AstraZeneca | 43 | $1,370 |
| Amgen | 71 | $1,097 |
| Novo Nordisk | 66 | $1,011 |
| Pfizer | 100 | $745 |
| Bayer | 26 | $549 |
| Supernus Pharmaceuticals, Inc. | 16 | $278 |
| Astellas Pharma US Inc | 13 | $199 |
| Abbott | 9 | $178 |
| Lilly USA, LLC | 9 | $164 |
| Amneal Pharmaceuticals LLC | 6 | $156 |
| Amarin Pharma, Inc. | 7 | $147 |
| GSK | 7 | $146 |
| Boehringer Ingelheim | 6 | $115 |
| Ascendis Pharma Endocrinology Inc | 3 | $72 |
| Paratek Pharmaceuticals, Inc. | 4 | $63 |
| Esperion Therapeutics, Inc. | 4 | $59 |
| Merck | 4 | $54 |
| Phathom Pharmaceuticals, Inc. | 7 | $50 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $49 |
| Genentech USA, Inc. | 2 | $39 |
| Biogen | 2 | $33 |
| Bristol Myers Squibb | 2 | $33 |
| Kvk-tech, Inc. | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Azurity Pharmaceuticals, Inc. | 1 | $28 |
| Ferring Pharmaceuticals Inc. | 1 | $27 |
| Convatec Inc. | 1 | $23 |
| IBSA Pharma Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Novartis | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Nevro Corp. | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,935 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 272 | $260,434 |
| JardianceEmpagliflozin | 235 | $189,960 |
| MounjaroTirzepatide | 156 | $181,595 |
| Repatha SureclickEvolocumab | 265 | $171,488 |
| EliquisApixaban | 212 | $162,788 |
| RybelsusSemaglutide | 57 | $64,888 |
| Lagevrio (Eua)Molnupiravir | 81 | $64,678 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 81 | $56,680 |
| XareltoRivaroxaban | 51 | $40,502 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 43 | $36,844 |
| TrulicityDulaglutide | 20 | $33,943 |
| GlyxambiEmpagliflozin/Linagliptin | 40 | $32,258 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 36 | $31,117 |
| FarxigaDapagliflozin Propanediol | 42 | $29,823 |
| SynthroidLevothyroxine Sodium | 220 | $25,081 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,011 | $325,322329 claims |
| Boehringer IngelheimJardiance, Trijardy Xr, Glyxambi, Synjardy Xr | $115 | $290,178354 claims |
| Lilly USA, LLCMounjaro, Trulicity | $164 | $215,538176 claims |
| PfizerEliquis, Paxlovid | $745 | $179,080257 claims |
| MerckLagevrio (Eua), Januvia, Janumet Xr, Belsomra, Steglujan | $54 | $104,628152 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $146 | $69,541104 claims |
| AbbVieSynthroid, Linzess, Creon | $2,026 | $57,856256 claims |
| Johnson & JohnsonXarelto | $16 | $40,50251 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,370 | $38,91056 claims |
| NovartisEntresto | $17 | $22,47527 claims |
| BayerKerendia | $549 | $21,56935 claims |
| Esperion Therapeutics, Inc.Nexlizet | $59 | $14,00826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Rochester
- Patrick ReaganRochester$9.4M
- Angela BrancheRochester$7.9M
- Patrick ConnorsRochester$4M
- Richard DunneRochester$1.6M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.